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Complex regional pain syndrome (CRPS) and fibromyalgia are chronic pain conditions of 
unexplained origins. In addition to symptoms in the diagnostic criteria, patients can report 
changes to vision and other sensations or bodily functions. It is unclear whether these are 
greater than would be expected due to normal ageing, living with chronic pain generally, or 
common co-morbidities of chronic pain such as depression or anxiety. We administered an on-
line survey evaluating the frequencies and types of self-reported somatic symptoms, bodily 
changes, and sensory sensitivity in respondents with CRPS (n=390), fibromyalgia (n=425), and 
both CRPS and fibromyalgia (‘CRPS+fibromyalgia’; n=88) compared to respondents with 
other chronic pain conditions (n=331) and pain-free controls (n=441). The survey assessed 
somatic symptoms (Patient Health Questionnaire-15), bodily changes, pain/discomfort/distress 
triggers, and pain intensifiers. We conducted ANCOVA’s with age, sex, the Patient Health 
Questionnaire-9 (measuring depression), the Generalized Anxiety Disorder-7, pain duration in 
years, hours of pain per day, and number of pain-related medical diagnoses as covariates. After 
controlling for covariates, respondents with CRPS and/or fibromyalgia reported more somatic 
symptoms, changes in movement and biological responses, pain/discomfort/distress triggers, 
and pain intensifiers than pain(-free) control groups. Fibromyalgia specifically related to 
changes in vision and hearing; urinary/intestinal function; and drinking and eating. CRPS 
changes related to changes in hair, skin, and nails; and infection and healing. The 
CRPS+fibromyalgia group presented with features of both disorders with minimal additional 
stressors or symptoms over and above these. Our findings suggest CRPS and fibromyalgia 





Complex regional pain syndrome (CRPS) and fibromyalgia are musculoskeletal pain 
conditions with distinct clinical phenotypes, but many overlapping features [35,36,38]. CRPS 
involves regional pain [4,52], whereas fibromyalgia involves widespread pain [18,19,56]. Both 
syndromes are associated with functional and structural changes in the central nervous system 
(CNS) [21,27,35,60]. People with CRPS and fibromyalgia show hyperalgesia (increased 
responses to painful stimuli) and allodynia (pain from a normally non-painful stimulation) 
[35,38], which is absent or less severe in other pain conditions such as arthritis [43], and has 
been attributed to central sensitisation [1,25,60]. Furthermore, there is some recent indication 
that CRPS and fibromyalgia are associated with condition-specific circulating, pain-sensitising 
autoantibodies [2,9,10,15]. 
In addition to heightened sensitivity to somatosensory stimuli, it is proposed that in 
both CRPS and fibromyalgia sensory input across many systems is amplified by the CNS, 
leading to enhanced sensory sensitivity for non-somatic stimuli [13,29]. CRPS and 
fibromyalgia are associated with greater sensitivity for visual, auditory, and olfactory stimuli 
compared to other pain disorders such as rheumatoid arthritis [8,14,16,29,46,55]. Compared to 
pain-free controls or people with other pain conditions, there is some evidence that people with 
CRPS show more vasomotor symptoms (e.g., differences in colour, temperature), trophic signs 
(e.g., changes in hair and nail growth), motor signs (e.g., restricted range of movement, tremor) 
[28,38]; and people with fibromyalgia report more fatigue, headache, nausea, hair loss [57], 
sensitivity for weather [41], and food intolerance [13]. Additionally, preliminary data shows 
that both people with CRPS and those with fibromyalgia report more bowel and bladder 
symptoms, and dryness of the mouth and eyes [38,59].  
People with CRPS and fibromyalgia report a range of sensory and bodily symptoms, 
many of which are not part of the diagnostic criteria for those disorders. It is unknown whether 
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the nature of such additional sensory and bodily symptoms differs between CRPS, fibromyalgia 
and other chronic pain conditions. This is because these symptoms have neither been compared 
using uniform assessment criteria [38], nor been considered in the context of  normal ageing, 
and common comorbidities of chronic pain such as depression and anxiety [42].   
The primary aim of this study was to systematically determine self-reported bodily 
changes and sensory sensitivity associated with CRPS and fibromyalgia. We selected these 
conditions as CRPS and fibromyalgia are both associated with disproportionately high service 
use and disability, have a poorly understood aetiology, are thought to involve central 
sensitisation, and people with these conditions seem to report unusual bodily changes and 
sensations more than people with other conditions. We were interested in whether having 
CRPS or fibromyalgia is associated with distinct profiles of bodily changes and sensory 
sensitivities over and above what could be expected due to anxiety, depression, living with 
chronic pain generally, and normal ageing. The secondary aim was to determine if having both 
CRPS and fibromyalgia, compared to having only one of these conditions, is associated with 
more severe clinical and pain-related characteristics (e.g., pain intensity, number of hours of 




2.1.1. Survey distribution and demographics 
We created an on-line survey using Qualtrics survey software [44] and collected data between 
July and December 2018. We distributed the online link to this survey among people with 
CRPS and pain-free controls who had previously taken part in other research in our lab. We 
specifically targeted people with CRPS and CRPS charities to make sure the group would be 
large enough to analyse. Additionally, we distributed the survey link amongst the Community 
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Participant Panel of the Psychology Department of the University of Bath, through patient 
newsletters and social media groups for a number of pain conditions, via our own social media, 
and to our friends and relatives. Given the relative rarity of CRPS, to attain a large sample we 
distributed the survey internationally. As we did not have sufficient resources to translate the 
survey, we stipulated that people should only respond if they felt comfortable reading and 
answering questions in English. We also stipulated that respondents should be aged 16 years 
or older. Information about the study was provided at the start of the survey alongside questions 
pertaining to informed consent. 
The survey took about 20 to 40 minutes to complete. If respondents closed the survey, 
the answers provided to that point were saved. Respondents had the opportunity to enter a prize 
draw for one of four £50 Amazon.co.uk vouchers (or a local equivalent). We obtained 
information about the location of respondents at the moment of filling in the survey using IP 
addresses and Qualtrics location data where possible. We asked for respondents’ age and 
gender. The research was approved by the committee on research ethics at the University of 
Bath (number 18-169), in accordance with the Declaration of the World Medical Association 
(www.wma.net). We uploaded a preregistration at the Open Science Framework [31]. See S1 
for all survey questions. 
 
2.1.2. Pain characteristics 
We asked whether respondents had experienced pain on most days for 3 months or more. If 
this question was answered with ‘no’, the survey directed the respondent to the next section. If 
this question was answered with ‘yes’, the survey directed the respondent to additional 
questions about their pain. Further questions about pain asked how long respondents had been 
experiencing pain (in years), the average hours of pain per day, whether they had received a 
medical diagnosis for their pain condition, what this diagnosis was, and who they had received 
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their diagnosis from. We predefined 15 pain-related medical diagnoses; including CRPS (we 
did not dissociate between CRPS I and CRPS II, as many patients do not know which type they 
have) and fibromyalgia (S1). An ‘other’ option was included with a free-text box for 
respondents to specify additional diagnoses; multiple items were counted as separate 
diagnoses. We categorized the diagnoses in the ‘other’ box based on the coding system for 
medical research categorisation (Supplementary Table 1), outlined by UK Clinical Research 
Collaboration (https://hrcsonline.net/health-categories/). Respondents were also asked what 
event or injury triggered the onset of their pain condition. We predefined seven events/injuries 
(S1) and included an ‘other’ option with a free-text box. Using a selection of ten predefined 
body parts and a free-text ‘other’ box (S1), respondents were asked to indicate where in their 
body they experienced pain over the past week. We measured pain intensity using the Numeric 
Pain Rating scale [26,47]. Respondents were asked to select a number on a sliding scale ranging 
from 0 (‘no pain’) to 10 (‘worst pain imaginable’) that best reflected the average level of their 
pain over the last week for each body part that they experienced pain in, and in their body 
overall. 
 
2.1.3. Depression and anxiety  
The Patient Health Questionnaire-9 (PHQ-9; S1) has nine questions with a score ranging from 
0 to 3 for each question (maximum score of 27). Scores indicate mild (10-14), moderate (15-
19), or severe (≥20) major depression [3,32].  
The Generalized Anxiety Disorder-7 (GAD-7; S1) scale has seven questions with a 
score ranging from 0 to 3 for each question (maximum score of 21). Scores indicate mild (5-
9), moderate (10-14), or severe (≥15) anxiety [50,51].  
 
2.1.4. Somatic symptoms 
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We included the Patient Health Questionnaire-15 (PHQ-15; S1) as a standardized and validated 
measure [33] of somatic symptoms. The PHQ-15 is a 14-item (for men and respondents who 
choose ‘other’ as their gender) or 15-item (for women) scale for the assessment of somatic 
symptoms. Respondents answer whether they are ‘not bothered at all’ (score 0) to ‘bothered a 
lot’ (score 2) by specific symptoms such as fainting spells or back pain over the past 4 weeks 
(maximum score of 30). Respondents could decline to answer a question about pain or 
problems during sexual intercourse, in which case this item was scored as ‘0’. Scores represent 
mild (6-10), moderate (11-15), or severe (>15) somatic symptoms.  
 
2.1.5. Bodily changes 
We created a survey item for the purposes of this study that asked which, if any, bodily changes 
respondents have experienced for the first time or that have become worse since the onset of 
their pain condition (for the pain groups) or over the last 2 years (for the pain-free control 
group). We predefined 46 bodily changes (see S1). We chose bodily changes based on the 
symptoms of CRPS (e.g., weakness, swelling in a limb, change in the way the nails grow [17]) 
and on complaints that people with CRPS or fibromyalgia had expressed to us (e.g., 
poor/double vision, skin that is more susceptible to sunburn or takes longer to heal when cut, 
intractable rashes). We categorized all predefined bodily changes into one of the following 
categories, which were visible to the respondents as sub-headings in the survey: (1) vision and 
hearing, (2) hair, skin, and nails, (3) infection and healing, (4) urinary/intestinal function, (5) 
drinking and eating, (6) movement, and (7) biological responses (e.g. sweating more/less, 
dizziness, feeling unusually cold/hot, loss/increase of sexual desire). We summed the number 
of items reported within each of these categories for each respondent. 
We included an ‘other’ option with a free-text box. We categorized the responses 
provided in the free-text box either into one of the existing categories or into one of the 
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following additional categories: (8) smell and taste (e.g., sensitivity to smell, change in taste), 
(9) skin sensitivity for external stimuli (e.g., hypersensitivity, numbness), (10) sensations 
within the body (e.g., burning sensations, pins and needles), (11) body representation (e.g., 
changed limb representation), (12) cognition (e.g., memory issues, word finding problems), 
(13) psychological (e.g., anxiety, depression), (14) energy and sleep (e.g., tiredness, sleep 
issues), and (15) other (e.g., change in voice, irregular periods). We summed the number of 
items reported within each of these categories for each respondent. Note that answers in the 
free-text box could include (spontaneously mentioned) non-bodily changes (e.g., psychological 
changes). It is possible that respondents who did not list any additional changes under the 
‘other’ category might have selected some of these items if they had been presented to them as 
a pre-defined option. The responses provided in the free-text box were, therefore, presented 
separately from the predefined bodily changes, as they do not provide the same information 
about the overall frequency of particular categories of symptoms.  
 
2.1.6. Sensory sensitivity  
Respondents were asked which, if any, sensory stimuli give them pain, discomfort, or distress 
(‘pain/discomfort/distress triggers’). We also asked those in the pain groups which, if any, 
sensory stimuli make their pain worse (‘pain intensifiers’). To achieve this, we predefined 11 
sensory stimuli based on complaints already identified in the literature, or that people with 
CRPS or fibromyalgia had expressed to us in our clinical and research work (e.g., consuming 
caffeine, bright lights; see S1). Additionally, we included an ‘other’ option with a free-text box. 
We summed the number of pain, discomfort, and distress triggers, and pain intensifiers that 
each respondent selected.  
With regard to the ‘other’ free-text option, we categorized the responses into one of the 
existing categories or into one of the following additional categories: people (e.g., crowds), 
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stress/emotions (e.g., fighting with a beloved one), moving (e.g., exercise, bending, walking), 
specific posture (e.g., standing, lying, sitting), pressure (e.g., touch, anything resting or 
bumping into the body), vibrations (e.g., vibrations like escalators), particular materials (e.g., 
clothing), weather (e.g., air pressure, humidity, rain, storm), water (e.g., baths, shower, hot, 
cold), illness/tiredness/period (e.g., flu, lack of sleep), and other (e.g., lack of food). The 
responses provided in the free-text box were presented separately from the predefined triggers. 
 
2.2 Statistical analyses 
2.2.1. Respondents 
We excluded respondents who had not answered all consent questions with ‘yes’, who were 
aged younger than 16 years, who did not finish at least the somatic symptoms questionnaire, 
and who provided inconsistent answers regarding pain duration (i.e., ‘yes’ on the question 
asking whether they experienced pain on most days for 3 months or more, and a number below 
3 months on the question asking how long they have been experiencing pain). We excluded 
double entries, identified by comparing IP addresses and provided answers. We inspected 
variables for outliers. Where answers were nonsensical, (e.g., a respondent reporting pain 
duration per day as more than 24 hours) we replaced the data with the mean for that group for 
that question, and we reported the number of cases in which this was done. We assigned 
respondents to one of five groups based on their declared diagnoses or lack thereof: CRPS, 
fibromyalgia, CRPS and fibromyalgia (‘CRPS+fibromyalgia’), pain control, or pain-free 
control. Respondents who reported not to have had pain for 3 months or more were allocated 
to the pain-free control group. The allocation of respondents to the CRPS, fibromyalgia, or 
CRPS+fibromyalgia groups were based on a respondent indicating one or both of these 
diagnoses, regardless of whether they indicated other pain diagnoses. Respondents were 




2.2.2. Demographics, depression, anxiety, and pain-related characteristics 
We calculated summary statistics about demographics, depression, anxiety and pain-related 
characteristics. We used one-way ANOVA’s and a Chi-square test (when more than 20% of 
cells had expected frequencies below 5, we used Fisher's exact test) to compare the groups. We 
used the Holm-Bonferroni method to correct for multiple comparisons for the post-hoc tests 
[22]. As the groups differed regarding all these variables (see results section), these variables 
were incorporated into the analyses addressing our research questions to control for their 
confounding effects. Respondents who indicated ‘other’ for their gender were excluded 
because they were too few for meaningful statistical analysis; however, we reported the 
descriptive statistics concerning this group for completeness.  
 
2.2.3. Somatic symptoms, bodily changes, and sensory sensitivity 
To determine whether there were any group differences in the reporting of somatic symptoms, 
bodily changes, and sensory sensitivity, we administered two-way ANCOVA’s with Group 
(CRPS, fibromyalgia, CRPS+fibromyalgia, pain control, pain-free control) and Gender (male, 
female) as the independent variables, and PHQ-15, the number of bodily changes per category, 
pain triggers, discomfort triggers, distress triggers, and pain intensifiers as the dependent 
variables. Age, PHQ-9, GAD-7, pain duration in years, hours of pain per day, and the number 
of pain-related medical diagnoses were included as covariates.  
We performed exploratory analyses to outline which specific bodily changes, 
pain/discomfort/distress triggers, and pain intensifiers were reported by respondents in the 
different groups (not corrected for possible confounds). We used Chi-square test (when more 
than 20% of cells had expected frequencies below 5, we used Fisher's exact test) to compare 
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the groups. For all analyses, we used the Holm-Bonferroni method to correct for multiple 
comparisons for the post-hoc tests. 
 
3. Results 
3.1. Demographics, depression, anxiety, and pain-related characteristics 
3.1.1 Demographics 
We received 2200 responses. Of these, 13 were excluded because respondents were younger 
than 16 years old; 485 respondents did not complete any questions about somatic symptoms, 
bodily changes, or sensory sensitivity; 6 respondents provided inconsistent answers regarding 
pain duration; and 14 responses were identified as double entries. In total, 1682 (76.5%) of 
responses were included in our analyses, of which 390 (23.2%) were categorised into the CRPS 
group, 452 (26.9%) into the fibromyalgia group, 88 (5.2%) into the CRPS+fibromyalgia group, 
311 (18.5%) into the pain control group, and 441 (26.2%) into the pain-free control group. We 
obtained information about the location of 1060 respondents (63.0%). Most were located in the 
United Kingdom (59.8%), the United States of America (14.4%), Australia (6.1%), the 
Netherlands (5.1%), Greece (4.0%), Canada (2.1%), and Germany (1.5%). Demographic and 
pain characteristics are listed in Table 1. Overall, the pain-free controls were younger than the 
other groups. There were more females in the fibromyalgia groups (with or without CRPS) 
than the other groups.  
 
3.1.2 Depression and anxiety 
Respondents with CRPS, fibromyalgia, and CRPS+fibromyalgia had higher depression (PHQ-
9) and anxiety (GAD-7) scores than pain controls and pain-free controls, and showed average 
scores consistent with moderate depressive and anxiety disorders (Table 1). Pain controls 
obtained higher depression and anxiety scores than pain-free controls, with averages consistent 
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with mild depressive and anxiety disorders. The pain-free controls showed no depressive and 
mild anxiety symptoms.  
 
3.1.3. Pain duration 
Respondents with fibromyalgia (with or without CRPS) reported to have experienced pain for 
about 13 years, which was longer than respondents with CRPS and pain controls (about 9-10 
years; Table 1). Respondents with CRPS and CRPS+fibromyalgia reported a similar number 
of hours of pain per day, which was more than the other pain groups. This was followed by the 
fibromyalgia group and finally the pain controls.  
 
3.1.4 Pain-related medical diagnoses 
Respondents with CRPS+fibromyalgia reported a greater number of pain-related medical 
diagnoses compared to the other groups, followed by respondents with fibromyalgia, 
respondents with CRPS, and the pain control group (Table 1). The pain-related medical 
diagnoses are summarised in Table 2. In all pain groups, back pain was reported as the most 
frequent (comorbid) diagnosis, followed by migraine and osteoarthritis. Almost half of 
respondents with fibromyalgia and one third of respondents with CRPS+fibromyalgia reported 
comorbid irritable bowel disease. Overall, respondents with fibromyalgia (with or without 
CRPS) reported other diagnoses with a significantly higher frequency than the other groups 
across the board. Respondents with CRPS reported co-morbid diagnoses with a similar or 
sometimes lower frequency than the other groups.  
 In Supplementary Table 1, we list the diagnoses that were mentioned in the ‘other’ box. 
These were mainly musculoskeletal disorders (e.g., Ehlers-Danlos syndrome, psoriatic 
arthritis, tendonitis, spinal stenosis) and neurological disorders (e.g., nerve damage, restless 
legs syndrome, intracranial hypertension, neuropathy). In Supplementary Figure 1, we show 
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which medical practitioner(s) provided the medical diagnoses. Respondents who reported as 
having CRPS and/or fibromyalgia mostly reported that these diagnoses were provided by a 
specialist doctor and/or general practitioner. In addition, CRPS was often diagnosed by 
physiotherapists which was less often the case for fibromyalgia.  
Information on events/injuries that triggered the pain condition and body parts in which 
respondents reported experiencing pain in are presented in S3 and S4, respectively.  
 
3.2. Somatic symptoms 
After adjusting for the covariates (gender, age, PHQ-9, GAD-7, pain duration, hours of pain 
per day, number of medical diagnoses), the five groups differed regarding somatic symptoms 
as measured with the PHQ-15 (Table 3). Respondents with fibromyalgia obtained scores that 
were significantly higher than all other groups except the CRPS+fibromyalgia group. The 
respondents with CRPS+fibromyalgia, had numerically higher scores than those with CRPS, 
pain controls, and pain-free controls, but only the difference to pain-free controls was 
significant. The next highest scores were for CRPS and pain controls who obtained similar 
scores that were also significantly higher than for the pain-free controls.  
 
3.3. Bodily changes 
Table 3 and Figure 1 show the proportion of selected bodily changes per pre-defined category 
for each group. When the covariates (gender, age, PHQ-9, GAD-7, pain duration in years, hours 
of pain per day, and the number of pain-related medical diagnoses) were controlled for, 
respondents with fibromyalgia reported significantly more changes in vision and hearing; 
urinary/intestinal function; drinking and eating; movement; and biological responses than the 
pain(-free) control groups. Respondents with CRPS reported more changes in hair, skin and 
nails; infection and healing; movement; and biological responses compared to the pain(-free) 
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control groups. The only category for which respondents with CRPS+fibromyalgia reported 
higher proportions of symptoms than respondents with only one of these conditions and both 
control groups was in biological responses. Exploratory analyses on individual items can be 
found in S5. 
 
3.4. Sensory sensitivity 
Table 3 shows the total number of pain, discomfort, and distress triggers, and pain intensifiers 
per group, adjusted for the covariates (gender, age, PHQ-9, GAD-7, pain duration, hours of 
pain per day, number of medical diagnoses). Respondents with CRPS and/or fibromyalgia 
reported more pain triggers and intensifiers than the other groups, whereas the pain controls 
did not differ from the pain-free controls. Respondents with fibromyalgia (with or without 
CRPS) reported a higher number of discomfort triggers, and respondents with both 
fibromyalgia and CRPS a higher number of distress triggers, than the other groups, although 
not all comparisons were significant. Exploratory analyses on individual items can be found in 
S6. 
 
3.5. Exploratory analysis: Predictors of somatic sensations, bodily changes and sensory 
sensitivity 
We performed multiple regression analyses (enter method) to evaluate the relationships 
between our covariates and outcome measures for respondents with CRPS or fibromyalgia. 
Somatic sensations were predicted by depression (PHQ-9), anxiety (GAD-7), and the number 
of medical diagnoses for both groups (Supplementary Table 6). The number of bodily changes 
was predicted by depression (PHQ-9), hours of pain per day, and the number of medical 
diagnoses for both groups; and additionally by pain duration for the fibromyalgia group. The 
number of pain/discomfort/distress triggers was predicted by the number of medical diagnoses 
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for both groups, and additionally by hours of pain per day for the fibromyalgia group. The 
number of pain intensifiers was predicted by pain duration in years for both groups, and 
additionally by the number of medical diagnoses for the CRPS group.  
 
4. Discussion 
The primary aim of this study was to determine whether having CRPS and/or fibromyalgia are 
associated with distinct profiles of bodily changes and sensory sensitivities above what could 
be expected due to anxiety, depression, living with chronic pain generally, and ageing.  
Respondents with CRPS and/or fibromyalgia reported more pain triggers and 
intensifiers compared to pain(-free) controls, whereas pain controls did not differ from pain-
free controls (Table 4). This indicates that higher sensory sensitivity is specifically associated 
with CRPS and fibromyalgia. It supports the proposed overlap between the disorders [7,34–
36,58] and suggests that the diseases spread beyond neural circuits related to sensory–motor 
processing for the extremities.  
The CNS is hypothesized to be involved in CRPS and fibromyalgia [23,24,39], with 
the nociceptive system being key. The nociceptive circuits become hypersensitive, increasing 
excitability to pain (central sensitisation). Evidence for CNS involvement includes that a subset 
of patients with CRPS develop hypoaesthesia, hypoalgesia, and hyperalgesia on the half of the 
body on the same side as the affected limb [11,30,48,49,54]. This anatomical distribution 
suggests CNS involvement [23]. Furthermore, there is evidence for psychophysical hyper 
excitability for pain stimuli in CRPS and fibromyalgia [12,39]. Sensitivity to non-
somatosensory stimuli, such as visual, auditory, and olfactory [8,14,16,29,46,55], could be 
explained by spreading of this hypersensitivity from the periphery to higher brain areas [53]. 
Other factors that might be related to central sensitisation could also play a role, such as 
genetics, sleep disturbance, and endocrine dysfunctions [60].  
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Central sensitisation is also involved in other pain conditions such as irritable bowel 
syndrome and chronic fatigue syndrome [36,61]. This association between the different pain 
conditions could explain why respondents with CRPS+fibromyalgia reported more pain-
related medical diagnoses (2.11 and 3.60 respectively) than the pain control group (1.63), and 
why respondents with CRPS+fibromyalgia reported even more diagnoses (5.00).  
Our data reflected the distinct clinical phenotypes of CRPS and fibromyalgia 
[34,35,43]. Respondents with CRPS and/or fibromyalgia reported more changes in movement 
and biological responses than the pain(-free) controls. Respondents with fibromyalgia (with or 
without CRPS) reported more changes in vision and hearing, urinary/intestinal function, and 
drinking and eating; and reported a higher number of discomfort triggers than other groups. 
This is consistent with previous findings where people with fibromyalgia reported, for 
example, more hearing difficulties [57], bowel symptoms (although also found in CRPS [38]), 
and food intolerance [13]. However, previous studies did not account for the confounds that 
we included in our analyses. Therefore, our results provide stronger support for the conclusion 
that such changes are specific to fibromyalgia, and greater than what could be due to broader 
factors such as ageing and living with chronic pain generally. Respondents with CRPS (with 
or without fibromyalgia) reported more changes in hair, skin, and nails than other groups, 
consistent with previous findings [38], and that several of these items are part of the CRPS 
diagnostic criteria [17]. However, they also reported more changes in infection and healing 
(e.g., skin takes longer to heal when cut or bruised), which are not in the diagnostic criteria.  
These findings imply that the sensitivity changes in CRPS and fibromyalgia are broader 
than those that relate to nociceptive systems [36]. It is not clear why some changes relate to 
CRPS and others to fibromyalgia. Typically, peripheral tissue damage causes a localized 
sensitisation process in CRPS whereas this is widespread in fibromyalgia. However, with time, 
CRPS pain can become more widespread and eventually fulfil the criteria for fibromyalgia 
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[36]. In our sample, respondents with CRPS frequently reported pain in body parts other than 
that affected by CRPS (in line with [37]). We did not see a clear relationship between pain 
chronicity and number of bodily changes. Disease progression is therefore not simply a 
predictor of the likelihood of reporting these changes. We did observe that the number of 
reported pain intensifiers was predicted by pain duration in years for both groups. We note that 
in CRPS, a dissociation can be made between ‘warm’ and ‘cold’ subtypes, with a higher 
contribution of inflammatory mechanisms to the former [6]. Results could, therefore, also be 
explained by differences between these subtypes.   
Compared to respondents with only CRPS or fibromyalgia, respondents with both 
reported a higher proportion of changes in biological responses, and a higher number of 
discomfort and distress triggers. As some of the changes in biological responses relate more to 
CRPS (e.g., one body part feeling unusually cold/hot) and others relate more to fibromyalgia 
(e.g., dizziness), this category reflects most strongly that people with both CRPS and 
fibromyalgia suffer from a wider range of symptoms than people who only have one of the 
conditions. However, there was no added distress for this group: they did not score higher 
regarding depression, anxiety, pain duration, hours of pain per day, or pain intensity. Because 
this group was small (n = 88), no firm conclusions can be drawn.  
Overall, our analyses of demographic, clinical, and pain-related characteristics are 
consistent with previous research. Respondents with pain had higher depression and anxiety 
than respondents without pain [20,40], with highest scores for respondents with CRPS and/or 
fibromyalgia [5,38]. There was a higher proportion of females in the pain groups than the pain-
free control group [5,20,38,40]. The onset of CRPS was mostly associated with physical trauma 
[35,38,58], and fibromyalgia with stressful situations (although this is not always found in 
literature [18,35,45]). Respondents with CRPS most frequently reported their limb(s) as being 
most painful, whereas respondents with fibromyalgia reported widespread pain [58]. 
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Respondents with pain reported more somatic symptoms (PHQ-15) than pain-free controls. 
Furthermore, respondents with fibromyalgia had the highest PHQ-15 scores, consistent with 
the fact that several of the items are in the fibromyalgia diagnostic criteria [56].  
 
4.1. Limitations and strengths 
Our study has some limitations. First, it is possible that people who experience unusual bodily 
sensations were more likely to respond, because we mentioned that the survey was about mood, 
bodily changes and other sensations. We conducted an online survey in order to include patients 
who live distant from our lab and/or are not able to travel. However, people with chronic pain 
possibly become more active on social media or in patient support groups once they have 
experienced their condition for a prolonged period. Future studies should focus on attaining 
unbiased samples. Second, groupings were based on self-reported diagnoses. To mitigate this, 
we asked respondents to report where they received their diagnoses. Most respondents reported 
receiving their diagnoses from an appropriately qualified practitioner. Third, we asked 
respondents with chronic pain to report their bodily changes and sensory sensitivity since the 
onset of their pain condition, whereas the pain-free controls reported the same over the past 
two years., because we estimated this was a reasonable time to have an accurate impression. 
However, the average duration of pain in our patient groups was 8.66-13.37 years, meaning 
that they were responding with regards to a longer time period. We controlled for this by 
including pain duration as a covariate (set to 0 for pain-free controls). Fourth, we distributed 
the survey internationally, and some of the English terms might not be consistent across 
countries or fully understood by non-native speakers. Finally, with regard to bodily changes, 
pain/discomfort/distress triggers, and pain intensifiers, we only recorded the presence or 
absence of symptoms. Thus, our results report on differences in the number of distinct bodily 
changes and sensory sensitivities reported by different patient groups and we are unable to 
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make inferences about the severity, intensity, or frequency (e.g. times felt per day) of these 
symptoms. However, results from these questions were broadly consistent with the results of 
the PHQ-15, which does give an overall scaled score, in that respondents with fibromyalgia 
had higher PHQ-15 scores and reported more bodily changes and sensory sensitivities.  
Our study also has several strengths. First, our sample size was large enough to compare 
the number and nature of self-reported bodily changes and sensory sensitivity between 
respondents with CRPS, fibromyalgia, other chronic pain conditions, and pain-free controls, 
while controlling for possible confounds. Second, this was the first study to assess discomfort 
and distress triggers, in addition to pain triggers. We found different patterns of results across 
these categories. Indeed, respondents with pain were more likely to report external stimuli as 
causing discomfort or distress than pain, which likely represents a negative effect on their 
quality of life that has not previously been considered. Therefore, these categories seem 
important to include in future studies. Third, this was the first study that separately evaluated 
respondents who self-reported as having both CRPS and fibromyalgia, demonstrating that the 
clinical and sensory profile of such patients is broadly similar to the overlap of respondents 
with only one of these conditions.  
 
4.2. Conclusions 
Respondents with CRPS and/or fibromyalgia reported more bodily changes and a greater 
number of sensory sensitivities than pain(-free) control groups.. These group differences cannot 
be attributed to sex differences, ageing, depression, anxiety, pain duration in years, hours of 
pain per day, and the number of pain-related medical diagnoses. Note that participants rated 
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Table 1. Demographics, depression, anxiety, and pain-related characteristics, means (SD) and percentages, split per group.  
 N CRPS N Fibromyalgia N CRPS+ 
Fibromyalgia 
N Pain controls N Pain-free controls Statistics  
Age, in years 390 45.64 (12.63)4,5 452 47.01 (12.04)4,5 88 45.65 (11.34)4,5 311 41.63 (16.71)1,2,3,5 441 34.63 (16.30)1,2,3,4 F(4) = 50.82, p < .001 
Gendera 390  452  88  311  441  χ2(4) = 98.27, p < .001 
- Female  346 (88.7%)2,4,5  421 (93.1%)1,4,5  84 (95.5%)4,5  247 (79.4%)1,2,3,5  320 (72.6%)1,2,3,4  
- Male  44 (11.3%)  25 (5.5%)  4 (4.5%)  58 (18.6%)  120 (27.2%)  
- Other  0  6 (1.3%)  0  6 (1.9%)  1 (0.2%)  
PHQ-9 (0-27) 314 15.62 (6.52)4,5 362 16.33 (6.06)4,5 70 16.73 (6.26)4,5 259 10.84 (7.00)1,2,3,5 387 5.99 (4.90)1,2,3,4 F(4) = 180.94, p < .001 
GAD-7 (0-21) 314 10.66 (6.06)4,5 362 11.01 (5.86)4,5 70 11.09 (5.95)4,5 259 7.90 (5.99)1,2,3,5 387 4.93 (4.58)1,2,3,4 F(4) = 73.03, p < .001 
Pain duration, in years 388 8.66 (7.95)2,3 452 13.37 (10.60)1,4 87 12.54 (10.02)1 310 9.72 (10.39)2 - - F(3) = 18.90, p < .001 
Hours of pain per dayb 390 18.49 (6.86)2,4 452 16.37 (7.17)1,3,4 88 19.57 (6.39)2,4 311 10.40 (8.06)1,2,3 - - F(3) = 83.94, p < .001 
Number of pain-related medical diagnoses 390 2.11 (1.57)2,3,4 452 3.60 (2.05)1,3,4 88 5.00 (3.49)1,2,4 311 1.63 (1.82)1,2,3 - - F(3) = 110.40, p < .001 
Abbreviations: Patient Health Questionnaire-9, PHQ-9; Generalized Anxiety Disorder-7, GAD-7. 
Note. The number of respondents differ per variable, as some respondents closed the survey before finishing it and only answers provided to that point were included.  
aWe did not include the ‘other’ group in the statistical comparison of gender, as the expected counts would be less than 5 in some cells. 
bOne respondent in the CRPS group and one in the fibromyalgia group provided pain durations per day as more than 24 hours. Their values were replaced by the group mean. 
Group mean differed significantly from 1CRPS, 2fibromyalgia, 3CRPS+fibromyalgia, 4pain controls, and 5pain-free controls.  
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Table 2. Numbers and percentages of medical diagnoses split by group. Note that respondents could report 
multiple diagnoses, thus percentages do not sum to 100. 
 CRPS  
(N = 390) 
Fibromyalgia  
(N = 452) 
CRPS+ 
Fibromyalgia 
(N = 88) 
Pain controls 
(N = 311) 
Statistics 
CRPS 390 (100%) 0 88 (100%) 0 - 
Fibromyalgia 0 452 (100%) 88 (100%) 0 - 
Back pain 80 (20.5%)2,3,4 187 (41.4%)1,4 46 (52.3%)1,4 92 (29.6%)1,2,3 χ2(3) = 58.52, p < .001 
Migraine 53 (13.6%)2,3 144 (31.9%)1,4 27 (30.7%)1,4 36 (11.6%)2,3 χ2(3) = 66.77, p < .001 
Osteoarthritis 47 (12.1%)2,3,4 129 (28.5%)1,4 28 (31.8%)1,4 60 (19.3%)1,2,3 χ2(3) = 40.63, p < .001 
Irritable Bowel Disease 34 (8.7%)2,3 183 (40.5%)1,4 27 (30.7%)1,4 26 (8.4%)2,3 χ2(3) = 169.00, p < .001 
Neuralgia 30 (7.7%)3 45 (10.0%)4 17 (19.3%)1,4 12 (3.9%)2,3 χ2(3) = 23.70, p < .001 
Hypermobility condition 27 (6.9%)2 79 (17.5%)1 12 (13.6%) 34 (10.9%) χ2(3) = 22.45, p < .001 
Plantar fasciitis 17 (4.4%)2 56 (12.4%)1,4 9 (10.2%) 10 (3.2%)2 χ2(3) = 30.61, p < .001 
Rheumatoid Arthritis 13 (3.3%)2,3,4 37 (8.2%)1 11 (12.5%)1 25 (8.0%)1 χ2(3) = 13.75, p = .003 
Endometriosis 11 (2.8%)3 29 (6.4%) 11 (12.5%)1,4 10 (3.2%)3 χ2(3) = 18.59, p < .001 
Cluster headache 7 (1.8%)2 27 (6.0%)1,4 4 (4.5%) 5 (1.6%)2 χ2(3) = 15.27, p = .002 
Stomach ulcer 6 (1.5%) 12 (2.7%) 2 (2.3%) 2 (0.6%) χ2(3) = 4.55, p = .208 
Crohn's Disease 2 (0.5%) 2 (0.4%) 0 0 p = .679a 
Multiple Sclerosis 1 (0.3%) 1 (0.2%) 2 (2.3%) 3 (1.0%) p = .059a 
Other (one or more other pain-
related diagnosis) 
69 (17.7%)2,4 162 (35.8%)1 24 (27.3%) 123 (39.5%)1 χ2(3) = 48.75, p < .001 
None 0 0 0 89 (28.6%) - 
Group mean differed significantly from 1CRPS, 2fibromyalgia, 3CRPS+fibromyalgia, 4pain controls, and 5pain-




Table 3. Somatic symptoms, bodily changes and sensory sensitivity scores. Means (SE) are depicted per group, 
taking into account the covariates (gender, age, PHQ-9, GAD-7, pain duration, hours of pain per day, number of 
medical diagnoses).  
 CRPS  
(N = 312) 
Fibromyalgia 
(N = 356) 
CRPS+ 
Fibromyalgia 
(N = 69) 
Pain controls 
(N = 253) 
Pain-free 
controls 
(N = 386) 
Statistics 
Somatic symptoms       
PHQ-15 11.27 (0.33)2,5 14.45 (0.43)1,4,5 12.57 (1.05)5 11.10 (0.29)2,5 9.28(0.28)1,2,3,4 F(4) = 21.83, p < .001 
       
Bodily changes (proportion of 
selected items per category) 
      
Vision and hearing 0.23 (0.02)2 0.35 (0.02)1,4,5 0.35 (0.06)4 0.18 (0.02)2,3,5 0.25 (0.02)2,4 F(4) = 11.15, p < .001 
Hair, skin, and nail 0.38 (0.02)2,4,5 0.19 (0.02)1,3 0.48 (0.05)2,4,5 0.15 (0.01)1,3,5 0.24 (0.01)1,3,4 F(4) = 40.63, p < .001 
Infection and healing 0.45 (0.03)4,5 0.35 (0.04)3 0.69 (0.10)2,4,5 0.29 (0.03)1,3 0.31 (0.03)1,3 F(4) = 6.40, p < .001 
Digestive function 0.25 (0.02) 0.33 (0.03)4 0.23 (0.06) 0.22 (0.02)2 0.24 (0.02) F(4) = 3.09, p = .015 
Drinking and eating 0.21 (0.05) 0.27 (0.02)4 0.21 (0.05) 0.18 (0.01)2 0.22 (0.01) F(4) = 3.34, p = .010 
Movement 0.56 (0.02) 0.49 (0.03) 0.59 (0.07) 0.40 (0.02) 0.30 (0.02) F(4) = 18.49, p < .001 
Biological responses 0.34 (0.01)3,4,5 0.31 (0.02)3,4,5 0.46 (0.05)1,2,4,5 0.19 (0.01)1,2,3 0.22 (0.20)1,2,3 F(4) = 20.97, p < .001 
       
Sensory sensitivity (number of 
selected items) 
      
Pain triggers 2.19 (0.16)4,5 1.74 (0.21)4 2.94 (0.51)4,5 1.03 (0.14)1,2,3 1.29 (0.14)1,2,3 F(4) = 8.95, p < .001 
Discomfort triggers 2.48 (0.21)2 3.67 (0.28)1,4 4.18 (0.68)4 2.11 (0.19)2,3,5 2.98 (0.19)4 F(4) = 8.19, p < .001 
Distress triggers 0.98 (0.18)3 1.10 (0.23) 2.68 (0.56)1,4 0.89 (0.15)3,5 1.52 (0.15)4 F(4) = 4.57, p = .001 
Pain intensifiers 3.69 (0.21)4 3.14 (0.28)4 4.58 (0.70)4 2.19 (0.21)1,2,3 - F(3) = 9.92, p < .001 
Abbreviations: Patient Health Questionnaire-15, PHQ-15;  




Table 4. Summary of group differences found for somatic symptoms, bodily changes, and sensory sensitivity. 
The summary reflects the statistical differences found after controlling for our covariates (gender, age, PHQ-9, 
GAD-7, pain duration, hours of pain per day, number of medical diagnoses). 
Comparison Results 
Pain controls vs pain-
free controls 
Pain controls reported more somatic symptoms and movement-related changes 
than pain-free controls. Pain-free controls reported more vision & hearing 
changes, hair, skin & nail changes, discomfort triggers, and distress triggers than 
pain controls.  
CRPS vs pain(-free) 
controls 
Respondents with CRPS reported more somatic symptoms, hair, skin & nail 
changes, infection & healing changes, movement-related changes, changes in 
biological responses, pain triggers, and pain intensifiers than pain(-free) controls.  
Fibromyalgia vs pain(-
free) controls 
Respondents with fibromyalgia reported more somatic symptoms, vision & 
hearing changes, urinary/intestinal function changes, drinking & eating changes, 
movement-related changes, changes in biological responses, pain triggers, 
discomfort triggers, and pain intensifiers than pain(-free) controls.  
CRPS vs fibromyalgia Respondents with CRPS reported more hair, skin & nail changes; and infection 
& healing changes than respondents with fibromyalgia. Respondents with 
fibromyalgia reported more somatic symptoms, vision & hearing changes and 
discomfort triggers than respondents with CRPS.  
CRPS+fibromyalgia vs 
CRPS or fibromyalgia 
only 
Respondents with CRPS+fibromyalgia reported more changes in biological 
responses than respondents with either CRPS or fibromyalgia. Respondents with 
CRPS+fibromyalgia reported more vision & hearing changes and distress triggers 
than respondents with CRPS, which did not differ from respondents with 
fibromyalgia. Respondents with CRPS+fibromyalgia reported more hair, skin & 
nail changes; and infection & healing changes than respondents with 






Figure 1. The proportion of selected bodily changes per category taking into account our 
covariates (gender, age, PHQ-9, GAD-7, pain duration, hours of pain per day, number of 










What is your age in years? 
▼ Under 16  ... 100 or older  
 
What is your gender? 





Have you been experiencing pain on most days for three months or more? 
o YES   
o NO    
 
On average, for how many hours per day do you normally feel pain? Please answer using numbers. For 
example, half an hour would be ".5", and two hours would be "2". 
Hours per day   ________________________________________________ 
 
For approximately how long have you been experiencing pain? Please answer in years  
and months. For example, 6 months would be “0" years and "6" months. 
Years   ________________________________________________ 
Months  ________________________________________________ 
 
Where in your body have you felt pain over the last week.  You can select as many responses as you like so 
please select all that apply. 
o Left arm and/or hand  
o Left leg and/or foot 
o Right arm and/or hand  
o Right leg and/or foot 
o Back  
o Stomach/abdomen  
o Chest  
o Groin/genitals  
o Neck  
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o Head  
o Other (Please specify. You can specify more than one thing if you wish) 
 
 
For each of the body parts that you have selected, please rate your average level of pain that you have 
experienced in that body part over the last week.  
 
No pain  Worst pain imaginable 




Please rate your average level of pain that you have experienced in your body OVERALL over the last 
week (that is, averaged across all your painful body parts). 
 
No pain  Worst pain imaginable 




Have you received a medical diagnosis for your pain condition? Here, a medical diagnosis is a diagnosis that has 
been determined by a medical practitioner such as a GP, specialist doctor (e.g. rheumatologist or pain 
specialist), physiotherapist, occupational therapist, or nurse. 
o YES   
o NO    
 
Please select all medical diagnoses that you have received for your pain condition. 
o Complex Regional Pain Syndrome (also known as Reflex Sympathetic Dystrophy, Causalgia, or 
Sudeck’s syndrome)    
o Rheumatoid Arthritis    
o Osteoarthritis   
o Plantar fasciitis   
o Fibromyalgia   
o Hypermobility   
o Back pain   
o Migraine   
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o Cluster Headache   
o Multiple Sclerosis    
o Neuralgia   
o Stomach ulcer   
o Endometriosis  
o Irritable Bowel Disease 
o Crohn’s Disease   
o Other (Please specify. You can specify more than one thing if you wish)_________________________ 
o I have not received any diagnosis for my pain condition   
 
You answered that you have received a medical diagnosis of [diagnosis that was selected]. Which medical 
practitioner diagnosed you with this condition (if you recall). Please select ALL that apply. 
o GP   
o Specialist doctor (e.g. rheumatologist or pain specialist)  
o Physiotherapist  
o Occupational therapist  
o Nurse  
o Other (Please specify)________________________________________________ 
o Don’t know/can’t remember  
 
 
Was there an event or injury that triggered the onset of your pain condition(s)?   
o YES    
o NO   
 
What was the event or injury that triggered the onset of your pain condition(s)?  
o Sprain  
o Fracture  
o Dislocation  
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o Surgery  
o Infection  
o Childbirth   
o Stressful situation such as bereavement, divorce, or loss of job (please specify. You can specify more 
than one thing if you wish) __________________________________________ 





Have you experienced any of the following [since the onset of your pain condition/over the past two years]*. 
Please only select those things that have started to bother you or have become worse since the onset of your 
pain condition. Select ANY that apply.   
* Respondents only saw one of the two options based on whether they reported to have chronic pain or not. 
o Blurred vision  
o Needing to change your glasses or contact lens prescription more often  
o Peripheral vision loss  
o Sensitivity to bright lights  
o Hearing loss  
o Tinnitus (Ringing in the ears)  
o Sensitivity to loud noises  
o Losing hair on your head  
o Losing hair on parts of your body other than your head  
o Extra hair growth on any part of your body   
o Skin rashes  
o Being more susceptible to sunburn  
o Changes in the texture of your skin  
o Changes in skin colour  
o Swelling (edema) in any body part  
o Changes in the nails of your hands (e.g. growing faster or slower, or being more brittle)  
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o Changes in your toenails (e.g. growing faster or slower, or being more brittle)  
o Allergic reactions on the skin  
o Increased susceptibility to illness (for example, becoming more frequently ill, or taking longer to 
recover from illness)  
o Finding your skin takes longer to heal when cut or bruised  
o Needing to urinate more often, or finding it difficult from stopping yourself urinate when you ‘need to 
go’   
o Needing to urinate less often, or finding it difficult to urinate   
o Loose bowels, diarrhoea, or needing to defecate more often   
o Constipation  
o Having a “sensitive stomach”  
o Nausea  
o Increase in weight  
o Decrease in weight  
o Allergic reactions to food and drink  
o Decreased alcohol tolerance   
o Increased alcohol tolerance  
o Weakness in any part of your body  
o Tremor in any part of your body 
o Problems with balance  
o Falling more frequently  
o Difficulties walking 
o Sweating more  
o Sweating less   
o Dizziness   
o Hay fever   
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o Loss of sexual desire   
o Increased sexual desire   
o Feeling unusually cold, or finding it difficult to get warm when you are cold   
o Feeling unusually hot, or finding it difficult to cool down when you are hot   
o Please specify anything else that you have experienced. Even if you have experienced a change to your 
body or its sensations that you think is odd, unusual, or sounds "a bit crazy", we are interested in hearing 
about it. You can specify more than one thing if you wish. In the next question you will have an opportunity 
to explain more about the changes and how they make you feel if you wish. Here, please just list any 





Do any of the following give you pain? Please select ANY that apply.*  
 
Do any of the following give you discomfort? Please select ANY that apply.*  
 
Do any of the following give you distress? Please select ANY that apply.* 
 
Do any of the following make your pain worse? Please select ANY that apply.* 
 
* The list of items below was used for each of the previous four questions: 
o Caffeine   
o Alcohol   
o Bright lights    
o Flashing lights   
o High-contrast images, such as black and white stripes spaced close together   
o Loud or unpleasant noises   
o The touch of clothing/water/breeze   
o Particular foods. If yes, please specify  __________________________________________________ 
o Particular smells. If yes, please specify  __________________________________________________ 
o Cold weather. if yes, then please specify from what temperature your pain starts______________    
o Warm or hot weather. If yes, then please specify from what temperature your pain starts ______  
o Other (Please specify. You can specify more than one thing if you wish)______________________ 
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Over the last 2 weeks, how often have you been bothered by any of the following problems?  
 Not at all  Several days  
More than 
half days  
Nearly every 
day  
Little interest or pleasure in doing things            o  o  o  o  
Feeling down, depressed, or hopeless           o  o  o  o  
Trouble falling/staying asleep, sleeping 
too much   o  o  o  o  
Feeling tired or having little energy     o  o  o  o  
Poor appetite or overeating                o  o  o  o  
Feeling bad about yourself – or that you 
are a failure or have let yourself or your 
family down   
o  o  o  o  
Trouble concentrating on things, such as 
reading the newspaper or watching 
television   
o  o  o  o  
Moving or speaking so slowly that other 
people could have noticed  o  o  o  o  
Or the opposite – being so fidgety or 
restless that you have been moving 
around a lot more than usual   
o  o  o  o  
Thoughts that you would be better off 
dead or of hurting yourself in some way   o  o  o  o  
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Generalized Anxiety Disorder (GAD-7) 
 
 
Over the last 2 weeks, how often have you been bothered by any of the following problems?  
 Not at all  Several days  
More than 
half days  
Nearly every 
day  
Feeling nervous, anxious, or on edge         o  o  o  o  
Not being able to stop or control 
worrying            o  o  o  o  
Worrying too much about different 
things    o  o  o  o  
Trouble relaxing      o  o  o  o  
Being so restless that it's hard to sit still    o  o  o  o  
Becoming easily annoyed or irritable      o  o  o  o  
Feeling afraid as if something awful 
might happen  o  o  o  o  
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Patient Health Questionnaire-15 (PHQ-15) 
 
During the past 4 weeks, how much have you been bothered by any of the following problems?       
 
 Not bothered at all Bothered a little Bothered a lot 
Stomach pain   o  o  o  
Back pain o  o  o  
Pain in your arms, legs, 
or joints (knees, hips, 
etc.)   
o  o  o  
Menstrual cramps or 
other problems with your 
periods  
o  o  o  
Headaches    o  o  o  
Chest pain  o  o  o  
Dizziness  o  o  o  
Fainting spells  o  o  o  
Feeling your heart pound 
or race  o  o  o  
Shortness of breath       o  o  o  
Constipation, loose 
bowels, or diarrhoea  o  o  o  
Nausea, gas, or 
indigestion  o  o  o  
Feeling tired or having 
low energy  o  o  o  







Bothered a lot 
Prefer not to 
say  
Not applicable  
Pain or problems 
during sexual 
intercourse  
o  o  o  o  o  
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S2. ‘Other’ pain-related medical diagnoses 
Supplementary Table 1. Numbers and percentages of people who reported one or more pain-related medical 
diagnoses in the ‘other’ box, that were grouped in the categories listed below. We categorized the diagnoses based 
on the coding system for medical research categorisation, outlined by UK Clinical Research Collaboration 
(https://hrcsonline.net/health-categories/). Note that these also include spontaneously reported non pain-related 
medical diagnoses, even though this was not asked for. 
 
CRPS  
(N = 390) 
Fibromyalgia  
(N = 452) 
CRPS+ 
Fibromyalgia 
(N = 88) 
Pain controls 
(N = 311) 
Musculoskeletal 41 (10.5%) 76 (16.8%) 10 (11.3%) 59 (19.0%) 
Neurological 11 (2.8%) 27 (6.0%) 8 (9.0%) 37 (11.9%) 
Inflammatory and immune system 8 (2.1%) 23 (5.1%) 5 (5.6%) 8 (2.6%) 
Oral and gastrointestinal 6 (1.5%) 14 (3.1%) 5 (5.6%) 6 (1.9%) 
Blood 4 (1.0%) 1 (0.2%) 2 (2.3%) 1 (0.3%) 
Injuries and accidents 3 (0.8%) 4 (0.9%) 2 (2.3%) 14 (4.5%) 
Reproductive health and childbirth 2 (0.5%) 8 (1.8%) 2 (2.3%) 4 (1.3%) 
Renal and urogenital 2 (0.5%) 3 (0.7%) 2 (2.3%) 1 (0.3%) 
Metabolic and endocrine 1 (0.3%) 7 (1.5%) 1 (1.1%) 2 (0.6%) 
Cardiovascular 1 (0.3%) 4 (0.9%) 3 (3.4%) 1 (0.3%) 
Skin 1 (0.3%) 2 (0.4%) 0 4 (1.3%) 
Mental health 1 (0.3%) 2 (0.4%) 0 2 (0.6%) 
Respiratory 0 3 (0.7%) 2 (2.3%) 2 (0.6%) 
Cancer and neoplasms 0 1 (0.2%) 0 4 (1.3%) 
Congenital disorders 0 1 (0.2%) 0 0 
Eye 0 1 (0.2%) 0 0 
Infection 0 0 2 (2.3%) 1 (0.3%)  
Ear 0 0 1 (1.1%) 0 
Stroke 0 0 0 0 





S3. Events/injuries that triggered the pain condition 
Fracture and surgery were reported more often by respondents with CRPS than respondents 
without CRPS, followed by sprain and dislocation (Supplementary Table 2). A stressful 
situation was reported more often by respondents with fibromyalgia than by respondents 
without fibromyalgia, followed by infection and childbirth. In general, respondents with 
CRPS+fibromyalgia tended to report the same inciting events as reported by respondents with 
only one of these conditions.  
 
Supplementary Table 2. Numbers and percentages of events/injuries that triggered the pain condition. Note that 
respondents could report multiple events/injuries, thus percentages do not sum to 100.  
 CRPS  
(N = 390) 
Fibromyalgia  
(N = 452) 
CRPS+ 
Fibromyalgia  
(N = 88) 
Pain controls 
(N = 311) 
Statistics 
None 27 (6.9%)2,4 227 (50.2%)1,3 10 (11.4%)2,4 154 (49.5%)1,3 χ2(3) = 234.91, p < .001 
Fracture 129 (33.1%)2,4 20 (4.4%)1,3,4 26 (29.5%)2,4 27 (8.7%)1,2,3 χ2(3) = 151.90, p < .001 
Surgery 126 (32.3%)2,4 32 (7.1%)1,3 34 (38.6%)2,4 33 (10.6%)1,3 χ2(3) = 126.77, p < .001 
Sprain 71 (18.2%)2,4 19 (4.2%)1,3 13 (14.8%)2 23 (7.4%)1 χ2(3) = 49.91, p < .001 
Dislocation 29 (7.4%)2 5 (1.1%)1,3,4 8 (9.1%)2 13 (4.2%)2 χ2(3) = 24.67, p < .001 
Stressful situation 28 (7.2%)2,3 113 (25.0%)1,4 15 (17.0%)1 28 (9.0%)2 χ2(3) = 63.80, p < .001 
Infection 13 (3.3%)2 44 (9.7%)1,4 6 (6.8%) 10 (3.2%)2 χ2(3) = 20.83, p < .001 
Childbirth 3 (0.8%)2,3 26 (5.8%)1 7 (8.0%)1 10 (3.2%) χ2(3) = 19.39, p < .001 
Other 116 (29.7%)2 95 (21.0%)1,3,4 31 (35.2%)2 92 (29.6%)2 χ2(3) = 13.79, p = .003 




S4. Body parts in which respondents reported experiencing pain in   
Most respondents with CRPS reported the leg and/or foot as being most painful, followed by the arm and/or hand (Supplementary Table 3). 
However, respondents with CRPS also often reported experiencing pain in parts of their body other than their limbs, especially the back, neck, and 
head. Respondents with fibromyalgia most frequently reported the back, neck, and head as being most painful, and the majority reported some 
pain in these body areas. Respondents with CRPS+fibromyalgia reported the leg and/or foot as being most painful, followed by the arm and/or 
hand, although they did experience pain in many other body parts as well, which was comparable with the fibromyalgia only group. More pain 
controls reported the back as being most painful, and approximately two-thirds of respondents in this group reported some pain in this area. The 
overall pain intensity for the most painful body part differed between groups, F(4) = 69.11, p < .001. Respondents with fibromyalgia (with or 
without CRPS) reported the highest pain intensity. Respondents with only CRPS reported higher pain intensity than pain controls. 
 
Supplementary Table 3. Numbers and percentages of the body parts where respondents reported any pain in the past week, and the average pain intensity reported across any 
painful body part, the most painful body parts over the past week, and the average pain intensity reported for the most painful body part. Note that respondents could report 
multiple body parts, thus percentages do not sum to 100.  
 CRPS (N = 390) Fibromyalgia (N = 452) CRPS+Fibromyalgia (N = 88) Pain controls (N = 311) 
 Experienced 
pain 






















Left leg and/or foot 193 (49.5%) 7.05 (2.05) 100 (25.6%) 7.87 (1.76) 359 (79.4%) 6.15 (2.00) 43 (9.5%) 8.20 (1.67) 72 (81.8%) 7.24 (2.18) 29 (33.0%) 8.51 (1.56) 124 (39.9%) 4.96 (2.04) 32 (10.3%) 6.48 (1.79) 
Right leg and/or foot 210 (53.8%) 7.04 (2.04) 124 (31.8%) 7.68 (1.82) 370 (81.9%) 6.23 (1.98) 47 (10.4%) 8.43 (1.46) 58 (65.9%) 7.46 (1.84) 20 (22.7%) 8.81 (1.38) 141 (45.3%) 5.09 (2.11) 43 (13.8%) 6.27 (2.10) 
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Left arm and/or hand 150 (38.5%) 6.27 (2.22) 60 (15.4%) 7.17 (2.35) 345 (76.3%) 5.61 (1.94) 21 (4.6%) 7.97 (1.81) 62 (70.5%) 6.25 (2.43) 15 (17.0%) 8.73 (1.72) 90 (28.9%) 4.64 (2.29) 14 (4.5%) 7.41 (2.36) 
Right arm and/or hand 151 (38.7%) 6.40 (2.07) 62 (15.9%) 7.12 (2.08) 359 (79.4%) 5.91 (2.04) 34 (7.5%) 8.43 (1.46) 58 (65.9%) 6.11 (2.47) 12 (13.6%) 9.27 (0.74) 96 (30.9%) 4.49 (2.09) 24 (7.7%) 5.92 (1.90) 
Back 176 (45.1%) 6.36 (2.32) 37 (9.5%) 8.46 (1.73) 415 (91.8%) 7.12 (2.02) 152 (33.6%) 8.33 (1.61) 75 (85.2%) 6.85 (2.18) 14 (15.9%) 9.01 (1.08) 203 (65.3%) 5.38 (2.14) 87 (28.0%) 6.13 (2.12) 
Stomach/abdomen 78 (20.0%) 5.46 (2.35) 12 (3.1%) 9.06 (0.97) 260 (57.5%) 5.77 (2.20) 31 (6.9%) 8.37 (1.29) 42 (47.7%) 6.30 (2.16) 7 (8.0%) 8.99 (1.24) 85 (27.3%) 5.39 (2.09) 32 (10.3%) 6.77 (1.81) 
Chest 56 (14.4%) 5.30 (2.32) 7 (1.8%) 7.29 (2.55) 219 (48.5%) 5.53 (2.31) 20 (4.4%) 8.60 (1.26) 29 (33.0%) 5.65 (2.34) 2 (2.3%) 9.25 (0.35) 45 (14.5%) 4.27 (2.02) 5 (1.6%) 6.62 (1.39) 
Groin/genitals 44 (11.3%) 5.64 (2.17) 6 (1.5%) 7.22 (1.71) 117 (25.9%) 5.66 (2.40) 9 (2.0%) 8.29 (1.96) 17 (19.3%) 6.28 (2.32) 3 (3.4%) 9.83 (0.29) 30 (9.6%) 4.78 (2.14) 4 (1.3%) 6.90 (0.89) 
Neck 131 (33.6%) 5.96 (2.23) 24 (6.2%) 8.01 (1.81) 401 (88.7%) 6.61 (2.14) 118 (26.1%) 8.39 (1.33) 63 (71.6%) 6.21 (2.46) 10 (11.4%) 9.07 (1.09) 133 (42.8%) 5.09 (2.22) 35 (11.3%) 6.26 (2.11) 
Head 107 (27.4%) 5.93 (2.31) 18 (4.6%) 7.79 (1.94) 357 (79.0%) 6.31 (2.17) 76 (16.8%) 8.47 (1.49) 49 (55.7%) 5.96 (2.43) 6 (6.8%) 9.70 (0.40) 97 (31.2%) 5.75 (2.14) 40 (12.9%) 7.09 (1.82) 
Other 60 (15.4%) 6.96 (2.24) 27 (6.9%) 8.36 (1.47) 138 (30.5%) 7.73 (1.73) 72 (15.9%) 8.33 (1.50) 26 (29.5%) 7.15 (2.10) 7 (8.0%) 9.34 (1.19) 66 (21.2%) 5.79 (2.50) 38 (12.2%) 6.59 (2.49) 




S5. Individual bodily changes 
From Supplementary Table 4 it is evident that no individual items are unique to any specific 
pain group, nor are there any that were not reported by any pain-free controls. Respondents 
with pain reported most bodily changes with greater frequency than respondents without pain, 
and respondents with CRPS and/or fibromyalgia  reported most bodily changes with greater 
frequency than pain controls. Respondents with CRPS (with or without fibromyalgia) reported 
with greater frequency than the other groups those individual items that are part of the CRPS 
diagnostic criteria (e.g., ‘swelling [oedema] in any body part’). However, respondents with 
fibromyalgia (without CRPS) also reported these items more frequently than the two control 
populations. Individual items that were reported with greater frequency by respondents with 
fibromyalgia (with or without CRPS) than the other groups include most items categorised 
under vision and hearing changes, ‘increased susceptibility to illness’, items related to bowel 
function (‘loose bowels, diarrhoea, or needing to defecate more often’, ‘constipation’), ‘allergic 
reactions to food and drink’, and ‘loss of sexual desire’. However, respondents with CRPS 
(without fibromyalgia) also reported these items more frequently than the two control 
populations. Individual items that were reported with greater frequency by the 
CRPS+fibromyalgia group than any other group included ‘losing the hair on your head’, 
‘finding your skin takes longer to heal when cut or bruised’, ‘falling more frequently’, 
‘difficulties walking’, and ‘hay fever’.  
The responses that were provided in the free-text box are depicted per category in 





Supplementary Table 4. Categorization of the predefined bodily changes that respondents could select as answer to the question: ‘Have you experienced any of the following 
since the onset of your pain condition/over the past two years? Please only select those things that have started to bother you or have become worse since the onset of your 
pain condition/over the past two years. Select ANY that apply.’ Values are not corrected for covariates. 
Bodily change CRPS  
(N = 390) 
Fibromyalgia  
(N = 452) 
CRPS+ 
Fibromyalgia 
(N = 88) 
Pain controls 
(N = 311) 
Pain-free  
controls  
(N = 441) 
Statistics 
Vision and hearing changes       
Blurred vision 142 (36.4%)2,3,4,5 258 (57.1%)1,4,5 51 (58.0%)1,4,5 67 (21.5%)1,2,3 88 (20.0%)1,2,3 χ2(4) = 183.04, p < .001 
Needing to change your glasses or contact lens prescription more often 94 (24.1%)2,3,4,5 172 (38.1%)1,4,5 35 (39.8%)1,4,5 47 (15.1%)1,2,3 75 (17.0%)1,2,3 χ2(4) = 82.38, p < .001 
Peripheral vision loss 20 (5.1%) 30 (6.6%)5 6 (6.8%) 8 (2.6%) 7 (1.6%)2 χ2(4) = 18.45, p = .001 
Sensitivity to bright lights 162 (41.5%)2,3,4,5 320 (70.8%)1,4,5 57 (64.8%)1,4,5 93 (29.9%)1,2,3,5 71 (16.1%)1,2,3,4 χ2(4) = 313.15, p < .001 
Hearing loss  46 (11.8%)2 96 (21.2%)1,4,5 14 (15.9%) 23 (7.4%)2 31 (7.0%)2 χ2(4) = 52.20, p < .001 
Tinnitus (Ringing in the ears) 109 (27.9%)2,5 214 (47.3%)1,4,5 34 (38.6%)4,5 68 (21.9%)2,3,5 43 (9.8%)1,2,3,4 χ2(4) = 168.13, p < .001 
Sensitivity to loud noises 215 (55.1%)2,3,4,5 320 (70.8%)1,4,5 65 (73.9%)1,4,5 96 (30.9%)1,2,3,5 55 (12.5%)1,2,3,4 χ2(4) = 381.42, p < .001 
       
Hair, skin, and nail changes       
Losing hair on your head 124 (31.8%)3,4,5 171 (37.8%)3,4,5 50 (56.8%)1,2,4,5 63 (20.3%)1,2,3 84 (19.0%)1,2,3 χ2(4) = 83.96, p < .001 
Losing hair on parts of your body other than your head* 67 (17.2%)4,5 52 (11.5%)3,4,5 21 (23.9%)2,4,5 18 (5.8%)1,2,3 11 (2.5%)1,2,3 χ2(4) = 75.68, p < .001 
Extra hair growth on any part of your body* 136 (34.9%)2,4,5 76 (16.8%)1,3,4,5 35 (39.8%)2,4,5 23 (7.4%)1,2,3 42 (9.5%)1,2,3 χ2(4) = 145.29, p < .001 
Skin rashes 150 (38.5%)4,5 212 (46.9%)4,5 41 (46.6%)4,5 59 (19.0%)1,2,3 56 (12.7%)1,2,3 χ2(4) = 164.25, p < .001 
Being more susceptible to sunburn 137 (35.1%)2,4,5 105 (23.2%)1,3,4,5 37 (42.0%)2,4,5 34 (10.9%)1,2,3 38 (8.6%)1,2,3 χ2(4) = 132.13, p < .001 
Changes in the texture of your skin* 250 (64.1%)2,4,5 153 (33.8%)1,3,4,5 54 (61.4%)2,4,5 54 (17.4%)1,2,3,5 49 (11.1%)1,2,3,4 χ2(4) = 331.21, p < .001 
Changes in skin colour* 300 (76.9%)2,4,5 55 (12.2%)1,3,5 58 (65.9%)2,4,5 22 (7.1%)1,3 16 (3.6%)1,2,3 χ2(4) = 799.53, p < .001 
Swelling (oedema) in any body part* 321 (82.3%)2,4,5 186 (41.2%)1,3,4,5 73 (83.0%)2,4,5 79 (25.4%)1,2,3,5 24 (5.4%)1,2,3,4 χ2(4) = 602.61, p < .001 
Changes in the nails of your hands (e.g., growing faster or slower, or 
being more brittle)* 
207 (53.1%)4,5 219 (48.5%)3,4,5 57 (64.8%)2,4,5 58 (18.6%)1,2,3,5 50 (11.3%)1,2,3,4 χ2(4) = 270.84, p < .001 
Changes in your toenails (e.g., growing faster or slower, or being more 
brittle)* 
228 (58.5%)2,4,5 152 (33.6%)3,4,5 57 (64.8%)1,2,4,5 41 (13.2%)1,2,3,5 26 (5.9%)1,2,3,4 χ2(4) = 368.09, p < .001 
Allergic reactions on the skin 105 (26.9%) 146 (32.3%) 34 (38.6%) 55 (17.7%) 45 (10.2%) χ2(4) = 83.62, p < .001 
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Infection and healing changes       
Increased susceptibility to illness (for example, becoming more 
frequently ill, or taking longer to recover from illness) 
184 (47.2%)2,3,4,5 279 (61.7%)1,4,5 60 (68.2%)1,4,5 106 (34.1%)1,2,3,5 60 (13.6%)1,2,3,4 χ2(4) = 256.33, p < .001 
Finding your skin takes longer to heal when cut or bruised 226 (57.9%)3,4,5 248 (54.9%)3,4,5 66 (75.0%)1,2,4,5 92 (29.6%)1,2,3,5 51 (11.6%)1,2,3,4 χ2(4) = 299.81, p < .001 
       
Urinary/intestinal function       
Needing to urinate more often, or finding it difficult from stopping 
yourself urinate when you ‘need to go’ 
141 (36.2%)2,3,5 277 (61.3%)1,4,5 57 (64.8%)1,4,5 95 (30.5%)2,3,5 81 (18.4%)1,2,3,4 χ2(4) = 209.01, p < .001 
Needing to urinate less often, or finding it difficult to urinate 59 (15.1%)2,4,5 34 (7.5%)1,5 12 (13.6%)4,5 15 (4.8%)1,3 9 (2.0%)1,23 χ2(4) = 58.37, p < .001 
Loose bowels, diarrhoea, or needing to defecate more often 110 (28.2%)2,3,5 245 (54.2%)1,4,5 44 (50.0%)1,4,5 83 (26.7%)2,3,5 52 (11.8%)1,2,3,4 χ2(4) = 205.7, p < .001 
Constipation 156 (40.0%)2,4,5 263 (58.2%)1,4,5 46 (52.3%)4,5 76 (24.4%)1,2,3,5 41 (9.3%)1,2,3,4 χ2(4) = 267.25, p < .001 
       
Drinking and eating changes       
Having a ‘sensitive stomach’ 149 (38.2%)2,5 258 (57.1%)1,4,5 39 (44.3%)5 111 (35.7%)5 94 (21.3%)1,2,3,4 χ2(4) = 122.94, p < .001 
Nausea 157 (40.3%)2,3,4,5 233 (51.5%)1,4,5 49 (55.7%)1,4,5 94 (30.2%)1,2,3,5 42 (9.5%)1,2,3,4 χ2(4) = 206.41, p < .001 
Increase in weight 215 (55.1%)2,4,5 318 (70.4%)1,4,5 56 (63.6%)4,5 114 (36.7%)1,2,3,5 111 (25.2%)1,2,3,4 χ2(4) = 214.94, p < .001 
Decrease in weight 77 (19.7%)5 57 (12.6%) 19 (21.6%)5 39 (12.5%) 36 (8.2%)1,3 χ2(4) = 29.16, p < .001 
Allergic reactions to food and drink 53 (13.6%)2,5 116 (25.7%)1,4,5 20 (22.7%)5 39 (12.5%)2,5 20 (4.5%)1,2,3,4 χ2(4) = 85.62, p < .001 
Decreased alcohol tolerance 78 (20.0%)2 163 (36.1%)1,4,5 20 (22.7%) 51 (16.4%)2 66 (15.0%)2 χ2(4) = 70.13, p < .001 
Increased alcohol tolerance 16 (4.1%) 28 (6.2%) 9 (10.0%) 12 (3.9%) 28 (6.3%) χ2(4) = 7.85, p = .100 
       
Changes related to movement       
Weakness in any part of your body* 339 (86.9%)4,5 386 (85.4%)4,5 79 (89.8%)4,5 184 (59.2%)1,2,3,5 73 (16.6%)1,2,3,4 χ2(4) = 630.75, p < .001 
Tremor in any part of your body* 215 (55.1%)2,3,4,5 199 (44.0%)1,3,4,5 62 (70.5%)1,2,4,5 65 (20.9%)1,2,3,5 22 (5.0%)1,2,3,4 χ2(4) = 341.54, p < .001 
Problems with balance 271 (69.5%)4,5 343 (75.9%)4,5 64 (72.7%)4,5 136 (43.7%)1,2,3,5 32 (7.3%)1,2,3,4 χ2(4) = 525.7, p < .001 
Falling more frequently 165 (42.3%)3,4,5 174 (38.5%)3,4,5 51 (58.0%)1,2,4,5 61 (19.6%)1,2,3,5 11 (2.5%)1,2,3,4 χ2(4) = 259.44, p < .001 
Difficulties walking 279 (71.5%)3,4,5 314 (69.5%)3,4,5 75 (85.2%)1,2,4,5 126 (40.5%)1,2,3,5 15 (3.4%)1,2,3,4 χ2(4) =, p < .001 
       
Changes in biological responses       
Sweating more* 261 (66.9%)4,5 279 (61.7%)4,5 63 (71.6%)4,5 90 (28.9%)1,2,3,5 76 (17.2%)1,2,3,4 χ2(4) = 320.54, p < .001 
Sweating less* 14 (3.6%) 11 (2.4%) 4 (4.5%) 11 (3.5%) 7 (1.6%) χ2(4) = 5.11, p = .276 
Dizziness 200 (51.3%)2,3,4,5 308 (68.1%)1,4,5 62 (70.5%)1,4,5 116 (37.3%)1,2,3,5 47 (10.7%)1,2,3,4 χ2(4) = 345.55, p < .001 
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Hay fever 56 (14.4%)3 93 (20.6%)3,4,5 31 (35.2%)1,2,4,5 34 (10.9%)2,3 54 (12.2%)2,3 χ2(4) = 42.74, p < .001 
Loss of sexual desire 202 (51.8%)2,4,5 281 (62.2%)1,4,5 56 (63.6%)4,5 113 (36.3%)1,2,3,5 57 (12.9%)1,2,3,4 χ2(4) = 264.6, p < .001 
Increased sexual desire 9 (2.3%)5 9 (2.0%)5 1 (1.1%) 7 (2.3%)5 48 (10.9%)1,2,4 χ2(4) = 60.03, p < .001 
Feeling unusually cold, or finding it difficult to get warm when you are 
cold 
192 (49.2%)2,4,5 280 (61.9%)1,4,5 52 (59.1%)4,5 97 (31.2%)1,2,3,5 45 (10.2%)1,2,3,4 χ2(4) = 292.00, p < .001 
Feeling unusually hot, or finding it difficult to cool down when you are 
hot 
162 (41.5%)2,3,4,5 274 (60.6%)1,4,5 56 (63.6%)1,4,5 70 (22.5%)1,2,3,5 36 (8.2%)1,2,3,4 χ2(4) = 327.83, p < .001 
One part or specific parts of your body feeling unusually cold* 252 (64.6%)2,4,5 145 (32.1%)1,3,4,5 48 (54.5%)2,4,5 58 (18.6%)1,2,3,5 38 (8.6%)1,2,3,4 χ2(4) = 346.54, p < .001 
One part or specific parts of your body feeling unusually hot* 160 (41.0%)2,4,5 108 (23.9%)1,3,4,5 43 (48.9%)2,4,5 35 (11.3%)1,2,3,5 13 (2.9%)1,2,3,4 χ2(4) = 239.19, p < .001 
* These items are part of the Budapest clinical diagnostic criteria for CRPS [1] 
Group mean differed significantly from 1CRPS, 2Fibromyalgia, 3CRPS+fibromyalgia, 4pain controls, and 5pain-free controls. 
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S6. Individual pain/discomfort/distress triggers and pain intensifiers 
From Supplementary Table 5 and Supplementary Figure 3 it is evident that there are no 
individual items that were uniquely reported by any one pain group. Nor are there any items 
that were not reported as triggering pain, discomfort, and distress for at least some pain-free 
controls, although the frequencies of these reports are lower than for the pain groups. Most 
items were reported by a higher proportion of respondents with CRPS and/or fibromyalgia 
compared to the pain control group.  
  Respondents with fibromyalgia reported more often that caffeine, alcohol, bright lights, 
flashing lights, high-contrast images, loud or unpleasant noises, particular foods and particular 
smells triggered pain, discomfort, or distress; or intensified pain compared to respondents with 
CRPS. Respondents with CRPS reported more often that the touch of clothing/water/breeze 
triggered pain and distress; and intensified pain compared to respondents with fibromyalgia.  
Respondents with CRPS+fibromyalgia reported loud or unpleasant noises and warm/hot 
weather to trigger and intensify pain more often compared to respondents with only one of 
these conditions. 
The responses that were provided in the free-text box are depicted per category in 
Supplementary Figure 4. The number of respondents who spontaneously mentioned additional 
items in the free-text box was lower than 10% per group, limiting how meaningful even 
qualitative group comparisons can be. 
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Supplementary Table 5. Proportion of respondents that choose each of the individual pain, discomfort, and distress triggers; and pain 
intensifiers.  
Sensory sensitivity CRPS  
(N = 339) 
Fibromyalgia  
(N = 403) 
CRPS+ 
Fibromyalgia 
(N = 79) 
Pain controls 
(N = 275) 
Pain-free  
controls  
(N = 393) 
Statistics 
Pain triggers       
Caffeine 7 (2.1%) 23 (5.7%)5 5 (6.3%) 10 (3.6%) 6 (1.5%)2 χ2(4) = 14.57, p = .006 
Alcohol 22 (6.5%)2,5 54 (13.4%)1,4,5 10 (12.7%)5 12 (4.4%)2,5 3 (0.8%)1,2,3,4 χ2(4) = 57.33, p < .001 
Bright lights 56 (16.5%)2.5 119 (29.5%)1,4,5 15 (19.0%)5 29 (10.5%)2,5 11 (2.8%)1,2,3,4 χ2(4) = 115.44, p < .001 
Flashing lights 59 (17.4%)4,5 94 (23.3%)4,5 12 (15.2%)5 22 (8.0%)1,2,5 7 (1.8%)1,2,3,4 χ2(4) = 93.77, p < .001 
High-contrast images 15 (4.4%) 29 (7.2%)5 5 (6.3%) 11 (4.0%) 6 (1.5%) χ2(4) = 15.89, p = .003 
Loud or unpleasant noises 101 (29.8%)3,4,5 115 (28.5%)3,4,5 35 (44.3%)1,2,4,5 41 (14.9%)1,2,3,5 13 (3.3%)1,2,3,4 χ2(4) = 138.03, p < .001 
The touch of clothing/water/breeze 238 (70.2%)2,4,5 116 (28.8%)1,3,4,5 56 (70.9%)2,4,5 31 (11.3%)1,2,3,5 4 (1.0%)1,2,3,4 χ2(4) = 528.39, p < .001 
Particular foods 31 (9.1%)2.5 97 (24.1%)1,4,5 13 (16.5%)5 27 (9.8%)2,5 16 (4.1%)1,2,3,4 χ2(4) = 82.05, p < .001 
Particular smells 17 (5.0%)5 32 (7.9%)4,5 10 (12.7%)4,5 4 (1.5%)2,3 3 (0.8%)1,2,3 χ2(4) = 42.84, p < .001 
Cold weather 224 (66.1%)4,5 240 (59.6%)3,4,5 59 (74.7%)2,4,5 79 (28.7%)1,2,3,5 20 (5.1%)1,2,3,4 χ2(4) = 406.56, p < .001 
Warm or hot weather 124 (36.6%)2,3,4,5 102 (25.3%)1,3,4,5 39 (49.4%)1,2,4,5 30 (10.9%)1,2,3,5 4 (1.0%)1,2,3,4 χ2(4) = 209.98, p < .001 
Other 71 (20.9%)4,5 58 (14.4%)5 13 (16.5%)5 34 (12.4%)1 5 (1.3%)1,2,3,4 χ2(4) = 71.38, p < .001 
       
Discomfort triggers       
Caffeine 30 (8.8%) 61 (15.1%) 9 (11.4%) 27 (9.8%) 42 (10.7%) χ2(4) = 8.66, p = .070 
Alcohol 41 (12.1%)2 82 (20.3%)1 10 (12.7%) 34 (12.4%) 66 (16.8%) χ2(4) = 13.16, p = .011 
Bright lights 156 (46.0%)2,5 286 (71.0%)1,4,5 45 (57.0%)4,5 108 (39.3%)2,3 140 (35.6%)1,2,3 χ2(4) = 119.48, p < .001 
Flashing lights 131 (38.6%)2 240 (59.6%)1,4,5 41 (51.9%)4,5 84 (30.5%)2,3 119 (30.3%)2,3 χ2(4) = 92.84, p < .001 
High-contrast images 98 (28.9%)2,3,5 198 (49.1%)1,4,5 37 (46.8%)1,4,5 60 (21.8%)2,3 76 (19.3%)1,2,3 χ2(4) = 106.62, p < .001 
Loud or unpleasant noises 153 (45.1%)2,5 239 (59.3%)1,4,5 44 (55.7%)4,5 97 (35.3%)2,3 137 (34.9%)1,2,3 χ2(4) = 63.82, p < .001 
The touch of clothing/water/breeze 144 (42.5%)4,5 202 (50.1%)4,5 32 (40.5%)4,5 43 (15.6%)1,2,3,5 25 (6.4%)1,2,3,4 χ2(4) = 238.81, p < .001 
Particular foods 38 (11.2%)2,3 106 (26.3%)1,4,5 19 (24.1%)1 35 (12.7%)2 55 (14.0%)2 χ2(4) = 41.65, p < .001 
Particular smells 26 (7.7%)2,3 109 (27.0%)1,4,5 16 (20.3%)1,5 27 (9.8%)2 24 (6.1%)2,3 χ2(4) = 97.47, p < .001 
Cold weather 106 (31.3%)5 160 (39.7%)4,5 28 (35.4%)5 74 (26.9%)2,5 39 (9.9%)1,2,3,4 χ2(4) = 96.30, p < .001 
Warm or hot weather 97 (28.6%)2,4,5 157 (39.0%)1,4,5 29 (36.7%)4,5 47 (17.1%)1,2,3 46 (11.7%)1,2,3 χ2(4) = 95.55, p < .001 
Other 40 (11.8%)5 53 (13.2%)5 7 (8.9%)5 22 (8.0%)5 8 (2.0%)1,2,3,4 χ2(4) = 36.18, p < .001 
       
Distress triggers       









Group mean differed significantly from 1CRPS, 2Fibromyalgia, 3CRPS+fibromyalgia, 4pain controls, and 5pain-free controls.  
Alcohol 20 (5.9%) 21 (5.2%) 6 (7.6%) 19 (6.9%) 21 (5.3%) χ2(4) = 1.48, p = .830 
Bright lights 54 (15.9%)2,5 98 (24.3%)1,4,5 10 (12.7%)5 34 (12.4%)2,5 15 (3.8%)1,2,3,4 χ2(4) = 70.50, p < .001 
Flashing lights 58 (17.1%)1,5 111 (27.5%)2,4,5 19 (24.1%)5 40 (14.5%)2,5 23 (5.9%)1,2,3,4 χ2(4) = 70.78, p < .001 
High-contrast images 24 (7.1%)2 69 (17.1%)1,4,5 9 (11.4%) 16 (5.8%)2 15 (3.8%)2 χ2(4) = 51.17, p < .001 
Loud or unpleasant noises 89 (26.3%)2,5 164 (40.7%)1,4,5 30 (38.0%)4,5 55 (20.0%)2,3,5 45 (11.5%)1,2,3,4 χ2(4) = 100.15, p < .001 
The touch of clothing/water/breeze 78 (23.0%)2,4,5 52 (12.9%)1,4,5 17 (21.5%)4,5 16 (5.8%)1,2,3 10 (2.5%)1,2,3 χ2(4) = 91.54, p < .001 
Particular foods 19 (5.6%) 45 (11.2%)5 6 (7.6%) 14 (5.1%) 10 (2.5%)2 χ2(4) = 26.69, p < .001 
Particular smells 20 (5.9%)2,5 62 (15.4%)1,4,5 11 (13.9%)4,5 13 (4.7%)2,3 7 (1.8%)1,2,3 χ2(4) = 62.94, p < .001 
Cold weather 69 (20.4%)4,5 77 (19.1%)4,5 17 (21.5%)4,5 27 (9.8%)1,2,3,5 7 (1.8%)1,2,3,4 χ2(4) = 79.50, p < .001 
Warm or hot weather 59 (17.4%)4,5 75 (18.6%)4,5 21 (26.6%)4,5 18 (6.5%)1,2,3 12 (3.1%)1,2,3 χ2(4) = 76.91, p < .001 
Other 30 (8.8%)5 47 (11.7%)5 7 (8.9%)5 15 (5.5%) 7 (1.8%)1,2,3 χ2(4) = 32.57, p < .001 
       
Pain intensifiers       
Caffeine 21 (6.2%) 44 (10.9%) 7 (8.9%) 27 (9.8%)  χ2(3) = 5.28, p = .153 
Alcohol 34 (10.0%) 66 (16.4%) 10 (12.7%) 27 (9.8%)  χ2(3) = 9.24, p = .026 
Bright lights 122 (36.0%)2,4 218 (54.1%)1,4 38 (48.1%)4 73 (26.5%)1,2,3  χ2(3) = 57.41, p < .001 
Flashing lights 100 (29.5%)2,4 170 (42.2%)1,4 30 (38.0%)4 53 (19.3%)1,2,3  χ2(3) = 41.78, p < .001 
High-contrast images 47 (13.9%)2 93 (23.1%)1,4 20 (25.3%)4 24 (8.7%)2,3  χ2(3) = 30.39, p < .001 
Loud or unpleasant noises 178 (52.5%)3,4 229 (56.8%)3,4 57 (72.2%)1,2,4 87 (31.6%)1,2,3  χ2(3) = 60.93, p < .001 
The touch of clothing/water/breeze 267 (78.8%)2,4 175 (43.4%)1,3,4 62 (78.5%)2,4 44 (16.0%)1,2,3  χ2(3) = 271.93, p < .001 
Particular foods 31 (9.1%)2 68 (16.9%)1,4 11 (13.9%) 26 (9.5%)2  χ2(3) = 13.09, p = .004 
Particular smells 18 (5.3%)2 74 (18.4%)1,4 11 (13.9%) 16 (5.8%)2  χ2(3) = 42.21, p < .001 
Cold weather 221 (65.2%)4 228 (56.6%)4 53 (67.1%)4 94 (34.2%)1,2,3  χ2(3) = 67.12, p < .001 
Warm or hot weather 155 (45.7%)2,4 134 (33.3%)1,3,4 43 (54.4%)2,4 40 (14.5%)1,2,3  χ2(3) = 82.01, p = .001 
Other 54 (15.9%) 56 (13.9%) 13 (16.5%) 40 (14.5%)  χ2(3) = 0.78, p = .854 
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S7. Predictors of somatic sensations, bodily changes and sensory sensitivity 
Supplementary Table 6. Outcomes of the multiple regression model of somatic sensations, 
bodily changes, pain/discomfort/distress triggers and pain intensifiers for respondents with 
CRPS and fibromyalgia.  
 CRPS  Fibromyalgia 
Dependent / independent 
variables 
F / B (95% CI) p R2  F / B (95% CI) p R2 
Somatic sensations (PHQ-15) F(7) = 28.07 < .001 .39  F(7) = 34.74 < .001 .41 
Gender 0.90 (-0.45 to 2.25) .190 .01  -0.07 (-1.77 to 1.62) .931 0 
Age -0.02 (-0.05 to 0.02) .422 0  -0.03 (-0.06 to 0) .069 0.01 
PHQ-9  0.25 (0.14 to 0.37) < .001* .06  0.29 (0.19 to 0.39) < .001* 0.09 
GAD-7  0.22 (0.10 to 0.34) < .001* .04  0.19 (0.10 to 0.29) < .001* 0.04 
Pain duration in years 0.05 (-0.01 to 0.11) .076 .01  -0.02 (-0.06 to 0.02) .431 0 
Hours of pain per day 0.04 (-0.03 to 0.11) .222 0  0.05 (-0.01 to 0.10) .111 0.01 
Number of medical diagnoses 0.57 (0.29 to 0.85) < .001* .05  0.30 (0.09 to 0.50) .005* 0.02 
        
Total number of bodily changes F(7) = 15.00  < .001 .26  F(7) = 25.20 < .001 .34 
Gender 0.89 (-1.41 to 3.19) .446 0  2.58 (-0.48 to 5.64) .098 .01 
Age 0.03 (-0.03 to 0.09) .362 0  0.02 (-0.04 to 0.08) .530 0 
PHQ-9  0.31 (0.12 to 0.51) .002* .03  0.43 (0.25 to 0.60) < .001* .01 
GAD-7  0.11 (-0.09 to 0.31) .284 0  0.07 (-0.11 to 0.24) .446 0 
Pain duration in years 0.09 (-0.01 to 0.18) .078 .01  0.10 (0.03 to 0.17) .009* .01 
Hours of pain per day 0.16 (0.04 to 0.27) .007* .02  0.12 (0.02 to 0.23) .019* .02 
Number of medical diagnoses 1.33 (0.86 to 1.81) < .001* .09  0.95 (0.58 to 1.32) < .001* .03 
        
Proportion of 
pain/discomfort/distress triggers 
F(7) = 7.24 < .001 .14  F(7) = 9.03 < .001 .15 
Gender 0.44 (-0.13 to 1.01) .126 .01  0.66 (-0.27 to 1.62) .160 .01 
Age 0 (-0.02 to 0.01) .652 0  -0.01 (-0.03 to 0.01) .205 0 
PHQ-9  0.04 ( -0.01 to 0.09) .124 .01  0.05 (-0.01 to 0.10) .081 .01 
GAD-7  0.05 (0 to 0.10) .062 .01  0.02 (-0.03 to 0.08) .377 0 
Pain duration in years 0.02 (0 to 0.04) .106 .01  0.02 (0 to 0.04) .059 .01 
Hours of pain per day 0.02 (-0.01 to 0.04) .301 0  0.04 (0.01 to 0.07) .020* .02 
Number of medical diagnoses 0.20 (0.08 to 0.32) .001* .04  0.19 (0.08 to 0.31) .001* .03 
        
Pain intensifiers F(7) = 5.39 < .001 .11  F(7) = 6.25 < .001 .11 
Gender 0.37 (-0.43 to 1.17) .364 0  0.97 (-0.29 to 2.22) .129 .01 
Age 0.01 (-0.01 to 0.04) .227 0  0 (-0.03 to 0.02) .729 0 
PHQ-9  0.04 (-0.03 to 0.11) .227 0  0.07 (0 to 0.15) .046* .01 
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GAD-7  0.04 (-0.03 to 0.11) .305 0  -0.05 (-0.12 to 0.02) .197 0 
Pain duration in years 0.04 (0.01 to 0.08) .008* .02  0.06 (0.03 to 0.09) < .001* .04 
Hours of pain per day 0.03 (-0.01 to 0.07) .091 .01  0.02 (-0.02 to 0.07) .280 0 
Number of medical diagnoses 0.23 (0.07 to 0.40) .006* .02  0.13 (-0.03 to 0.28) .105 .01 
Abbreviations: Patient Health Questionnaire-9, PHQ-9; Patient Health Questionnaire-15, PHQ-15; Generalized 
Anxiety Disorder-7, GAD-7. 
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Supplementary Figure 1. Percentages of medical practitioners that respondents received their 
medical diagnosis from, split per medical diagnosis. Note that respondents could report 
multiple practitioners who had provided the medical diagnosis, thus percentages do not sum to 
100. * ‘Other’ medical diagnoses indicate the number of respondents who received 1 or more 






Supplementary Figure 2. Proportion of bodily changes provided in the free-text box, depicted 
per category. Answers in the free-text box were categorized in the existing categories or in new 
categories. Error bars depict 95% confidence intervals. Note that these means are not corrected 





Supplementary Figure 3. Proportion of respondents who selected each of the pain, 
discomfort, distress triggers, and pain intensifiers. Error bars depict 95% confidence intervals. 








Supplementary Figure 4. Proportion of pain/discomfort/distress triggers provided in the free-
text box, depicted per category. Answers in the free-text box were categorized in the existing 
categories or in new categories. Error bars depict 95% confidence intervals. Note that these 
means are not corrected for our covariates, nor did we compare groups statistically. 
 
